Mark Niquette

Nancy Cook, a Bloomberg political reporter, and Mark Niquette, a reporter focused on the real economy, dive into Trump's transformative economic agenda. They discuss how sweeping tariffs have reshuffled global trade, creating uncertainty for businesses. Cook highlights the challenges of evaluating these policies due to constant changes, while Niquette notes the lack of major reshoring despite tariff intentions. They also touch on deregulation, labor shortages, and the long-term implications of Trump’s populist economic themes for the Republican Party.

Mark Niquette, a Bloomberg News reporter, highlights which industries are most at risk in the upcoming election, including banks and electric vehicles. Kim Henriksson, CFO at EQT Partners, shares insights on IPO valuations tied to geopolitical risks. Isabelle Freidheim from Athena Capital sheds light on market uncertainties surrounding these IPOs. Finally, Sarah Ponczek, a financial advisor at UBS, discusses how the election's outcome will shape investment strategies. Tune in for a lively discussion on how politics and economics intertwine!

UAW striking workers' concerns, potential of AI in healthcare, VC investing in deep technology, Google's user data used by police, reducing carbon emissions, impacts of fluctuating rates on consumption spending and equity market weakness

Mark Niquette, a Bloomberg Real Economy team reporter, discusses the upcoming U.S. presidential election and its potential economic impact. Stuart Paul analyzes the Federal Reserve's interest rate strategy amidst public concerns. Dan Hansen evaluates the UK's new budget and its influence on the Bank of England. Tatsuo Yoshida shares insights on Japanese automakers as they prepare for earnings season. George Milling Stanley highlights the factors driving gold prices to new heights, including geopolitical tensions and economic policies.

Robinhood CEO discusses new credit card, Boeing leadership changes are analyzed, Apple's iPhone shipments drop in China, Carnival earnings reviewed, and Novo Nordisk's acquisition of Cardior Pharmaceuticals discussed.